-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, at the 113th American Association for Cancer Research (AACR) annual meeting in 2022, Hansoh Pharma announced the research data of the single-agent phase I ramp-up trial of its self-developed class 1 innovative drug PI3Kα inhibitor HS-10352-101
This report was presented by Prof.
So far, China has not approved any PIK3CA inhibitors for marketing
The full name of PI3K is phosphatidylinositol-3-kinase, which is an important signaling pathway in cells and one of the key targets for the development of new anti-tumor drugs in recent years
According to the Insight database, there are a total of 36 PI3Kα projects under research in the world, of which 2 have been approved for marketing and 3 are in Phase III clinical trials
PI3Kα target details
From: Insight Database
Edit: plus one